Weitere Artikel dieser Ausgabe durch Wischen aufrufen
The first disease-specific quality-of-life questionnaire in patients with drug hypersensitivity, Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q), was developed and validated recently. The aim of this study was to assess validity, reliability and responsiveness to interventions of the Turkish version of the DrHy-Q.
The Turkish version of the DrHy-Q was administered to prospectively enrolled 736 patients with drug hypersensitivity from ten allergy units. To assess validity, all patients completed the validated Turkish version of Psychological General Well-Being Index (PGWBI). For test–retest reliability, 182 patients completed the DrHy-Q 1 week after the first questionnaire administration without any intervention. Responsiveness was assessed on 97 patients who had a DrHy-Q recorded at a follow-up visit after the intervention.
The internal consistency and test–retest reliability of the scale were adequate (Cronbach’s alpha = 0.934, intra-class correlation coefficient = 0.783). The DrHy-Q scores showed weak negative correlations with the PGWBI total and domain scores (r = − 0.378 to −0.254, p < 0.001). DrHy-Q was able to discriminate the patients with one drug hypersensitivity reaction from the patients with two and above two reactions (p = 0.012 and p < 0.001, respectively), and the patients who experienced a respiratory reaction from the patients who did not (p = 0.018). However, it did not discriminate the patients with comorbid disease including psychiatric comorbidity (p > 0.05). The baseline DrHy-Q scores were significantly higher than the post-intervention scores (p = 0.008).
The Turkish version of DrHy-Q is reliable and valid for evaluating quality of life in patients with drug hypersensitivity, and it appeared responsive to interventions.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:
Baiardini, I., Pasquali, M., Giardini, A., Specchia, C., Passalacqua, G., Venturi, S., et al. (2003). Rhinasthma: A new specific QoL questionnaire for patients with rhinitis and asthma. Allergy, 38, 289–294. CrossRef
Bavbek, S., Celik, E. G., Aydın, O., Oner Erkekol, F., Kursun, N., Mungan, D., et al. (2012). Prevalence of hypersensitivity reactions against drugs among adult population in Turkey: A self reported survey. Journal of Public Health, 20, 585–592. CrossRef
Bavbek, S., Pasaoğlu, G., Canat, S., Sağduyu, G., & Mısırlığıl, Z. (2006). Allergy to drugs: How important for psychological epidemiology? International Journal on Psychiatry in Clinical Practice, 10(1), 64–68. CrossRef
Baiardini, I., Braido, F., Fassio, O., Calia, R., Canonica, G. W., Romano, A., & DrHy-Q PROs Research Italian Group. (2011). Development and validation of the Drug Hypersensitivity Quality of Life Questionnaire. Annals of Allergy, Asthma & Immunology, 106, 330–335. CrossRef
Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. Psychometrika, 16, 297–334. CrossRef
Streiner, D. L., & Norman, G. R. (1995). Health measurement scales. A practical guide to their development and use (2nd ed., pp. 104–126). New York: Oxford Medical Publications.
Fleiss, J. L., Levin, B., & Paik, M. C. (2003). Statistical methods for rates and proportions. Hoboken, NJ: Wiley. CrossRef
Ay, S., Koldaş Doğan, Ş., Evcik, D., Gök, H., Tur, B. S., & Gökmen, D. (2010). Reliability and validity of psychological general well-being index in Turkish population. Turkish Journal of Physical Medicine and Rehabilitation, 56, 161–169.
Dupuy, H. (1984). The psychological general well-being (PGWB) index. In N. K. Wenger, M. E. Mattson, C. D. Furberg, & J. Elinson (Eds.), Assessment of quality of life in clinical trials of cardiovascular therapies (pp. 170–183). Greenwich, CT: Le Jacq Publishing Inc.
Ertam, I., Kitapcioglu, G., Aksu, K., et al. (2009). Quality of life and its relation with disease severity in Behçet’s disease. Clinical and Experimental Rheumatology, 27, S18–S22. PubMed
Pallant, J. F., Kenan, A. M., Misajon, R., Conaghan, P. G., & Tennant, A. (2009). Measuring the impact and distress of osteoarthritis from the patients’ perspective. Health and Quality of Life Outcomes, 29(7), 37. CrossRef
Cohen, J. (1977). Statistical power: Analysis for behavioral sciences. New York: Academic Press.
Muthen, L. K., & Muthen, B. O. (1998–2007). Mplus user’s guide, 5th edn. Los Angeles, CA: Muthen and Muthen.
US Food and Drug Administration (FDA). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/Guidelines/UCM193282.pdf
Baiardini, I., Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., et al. (2010). Global allergy and asthma European network. Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: A GA(2)LEN task force position paper. Allergy, 65(3), 290–295. PubMedCrossRef
- Turkish version of the Drug Hypersensitivity Quality of Life Questionnaire: assessment of reliability and validity
Seçil Kepil Özdemir
Beyza Doğanay Erdoğan
Adile Berna Dursun
Ali Fuat Kalyoncu
Gülden Paşaoğlu Karakış
Ferda Öner Erkekol
- Springer International Publishing
Neuer Inhalt/© Stellmach, Neuer Inhalt/© Maturus, Pluta Logo/© Pluta